417 Evaluating the activity of the p53-MDM2 inhibitor NDD0005 in Ewing sarcoma
Pecqueur, J, Vormoor, B, Zhao, Y, Newell, H
Published in European journal of cancer (1990) (01.11.2014)
Published in European journal of cancer (1990) (01.11.2014)
Get full text
Journal Article
A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia
Vormoor, B., Veal, G. J., Griffin, M. J., Boddy, A. V., Irving, J., Minto, L., Case, M., Banerji, U., Swales, K. E., Tall, J. R., Moore, A. S., Toguchi, M., Acton, G., Dyer, K., Schwab, C., Harrison, C. J., Grainger, J. D., Lancaster, D., Kearns, P., Hargrave, D., Vormoor, J.
Published in Pediatric blood & cancer (01.06.2017)
Published in Pediatric blood & cancer (01.06.2017)
Get full text
Journal Article
289 Assessment of a DNA-PK Inhibitor as a Chemo-potentiating Agent in Osteosarcoma
O'Reilly, E, Vormoor, B, Kyle, S, Newell, H
Published in European journal of cancer (1990) (01.11.2012)
Published in European journal of cancer (1990) (01.11.2012)
Get full text
Journal Article
S255: EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) MATURE B‐CELL NON‐HODGKIN LYMPHOMA (NHL): THE PHASE II BIANCA STUDY
Minard‐Colin, V., Buechner, J., Locatelli, F., Gonzalez Martinez, B., Vormoor, B. J., Cooper, S., Krueger, J., Napolitano, S., Attarbaschi, A., Baruchel, A., Ghorashian, S., Hermiston, M. L., Hiramatsu, H., Ifversen, M., John, S., Khaw, S. L., O'Brien, T. A., Phillips, C. L., Diaz de Heredia, C., Tomizawa, D., Vettenranta, K., Wayne, A. S., Newsome, S., Awasthi, R., Redondo, S., Masood, A., Maude, S. L., Burkhardt, B.
Published in HemaSphere (01.06.2022)
Published in HemaSphere (01.06.2022)
Get full text
Journal Article